Serotonin News and Research

Latest Serotonin News and Research

Addiction to high calorie fat rich food: likened to cocaine and heroin addiction

In a new research our worst fears are confirmed – fatty, fried and fattening foods are addictive. The addiction with these delicious ‘yummies’ may be as potent as that with cocaine or heroin. The study was conducted on experimental animals, rats in this case. When fed with fatty foods in great quantities these rats showed a compulsive need to eat.

29 Mar 2010

USPTO allows Pisgah Labs' patent application regarding imipramine pamoate

Pisgah Labs, a drug product development company and an active pharmaceutical ingredient manufacturer (API) located in western North Carolina, has received a patent allowance in a series of patent applications. The US Patent & Trademark Office (USPTO) has notified Pisgah Labs, Inc. that a patent application related to a therapeutically significant family of pharmaceutical polymorphic compositions of imipramine pamoate has been allowed. The patent application also includes methods of manufacturing, purifying and use in pharmaceutical preparations.

26 Mar 2010

Changing drug therapy can help breast cancer patients get full benefit of tamoxifen treatment

26 Mar 2010

Changing drug therapy can help breast cancer patients get full benefit of Tamoxifen

Recently published research has shown that some breast cancer patients taking tamoxifen may not be getting the full benefit of their treatment because they have also been taking selective serotonin reuptake inhibitors (SSRIs), prescribed drugs that inhibit the effect of an important enzyme. Now researchers have developed a strategy for overcoming this problem, the seventh European Breast Cancer Conference (EBCC7) in Barcelona will hear today (Wednesday).

25 Mar 2010

Clinical Data completes NDA submission for vilazodone

Clinical Data, Inc., today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vilazodone for the treatment of major depressive disorder (MDD). Vilazodone is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. The Company expects that the NDA submission, if accepted, will be subject to a standard review.

23 Mar 2010

IDT: Military application of Transcendental Meditation for preventing war and terrorism

A leading scientific journal in Pakistan, The Journal of Management & Social Science, recently published a paper titled "A New Role for the Military: Preventing Enemies from Arising-Reviving an Ancient Approach to Peace," indicating that the military application of the Transcendental Meditation technique has merit. The paper discusses how militaries worldwide could use the Transcendental Meditation- and TM-Sidhi- program, founded by Maharishi Mahesh Yogi, as a non-religious and scientifically verified way to prevent war and terrorism. When used in a military context, these meditation practices are known as Invincible Defense Technology (IDT).

23 Mar 2010

StockPreacher.com: ACAD reports net loss of $8.7M for fourth-quarter of 2009

StockPreacher.com announces an investment report featuring ACADIA Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

17 Mar 2010

Antidepressants effective against depression in patients suffering from physical illnesses

Antidepressants are effective against depression in patients suffering from physical illnesses, according to a new systematic review by Cochrane researchers at King's Health Partners Academic Health Sciences Centre in the UK. The researchers found the drugs were more effective than placebos at treating depression in these patients.

17 Mar 2010

Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly

Ipsen announced today the initiation of dosing in two phase II clinical studies to evaluate efficacy and safety of BIM 23A760 in two groups of patients, one suffering from carcinoid syndrome due to neuroendocrine tumors, the other from acromegaly.

15 Mar 2010

Sleep disorders may increase risk of cardiovascular and metabolic diseases

Many Americans will lose an hour of sleep on March 14, the first day of daylight-saving time, when clocks are set ahead one hour at 2 a.m. local standard time—making it harder to wake up, causing difficulty in staying alert and increasing the chance of sleepy-driving car crashes.

11 Mar 2010

DSPA's lurasidone NDA accepted for FDA review

Dainippon Sumitomo Pharma America, Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd., today announced that the U.S. Food and Drug Administration recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review.

10 Mar 2010

AssureRx Health adds CYP1A2 gene to laboratory-developed pharmacogenetic test

AssureRx Health, Inc., a personalized medicine company focused on pharmacogenetics to aid in the treatment of patients with psychiatric disorders, today announced that it has added a fifth gene, CYP1A2, to its laboratory-developed pharmacogenetic test.

9 Mar 2010

Some anti-depressant drugs associated with increased chance of developing cataracts: Study

Some anti-depressant drugs are associated with an increased chance of developing cataracts, according to a new statistical study by researchers at the University of British Columbia, Vancouver Coastal Health Research Institute and McGill University.

9 Mar 2010

Moderating treatment response in depression: Role of personality factors

A study published in the current issue of Psychotherapy and Psychosomatics addresses the role of personality factors in moderating treatment response in depression.

8 Mar 2010

Study indicates GABA neurotransmitters could play a key role in major depressive disorder

The next advance in treating major depression may relate to a group of brain chemicals that are involved in virtually all our brain activity, according to a study published today in Biological Psychiatry.

2 Mar 2010

Scopolamine drug: A rapid-acting antidepressant for depression symptoms

Conventional antidepressant treatments generally require three to four weeks to become effective, thus the discovery of treatments with a more rapid onset is a major goal of biological psychiatry. The first drug found to produce rapid improvement in mood was the NMDA glutamate receptor antagonist, ketamine.

1 Mar 2010

Arena Pharmaceuticals' lorcaserin NDA: FDA assigns PDUFA date

Arena Pharmaceuticals, Inc. announced today that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of October 22, 2010, for the review of the lorcaserin New Drug Application (NDA). The acceptance of the lorcaserin NDA filing confirms that the application is sufficiently complete to permit a substantive review, and the PDUFA date is the goal date for the FDA to complete its review of the NDA.

26 Feb 2010

Fisher Wallace Cranial Stimulator prescribed to patients suffering from depression, anxiety and insomnia

Fisher Wallace Laboratories today announced that two psychiatry professors at Columbia University, Dr. Richard Brown and Dr. Andres San Martin, have prescribed the Fisher Wallace Cranial Stimulator to more than 250 patients suffering from depression, anxiety and insomnia.

25 Feb 2010

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

A new study found that fluoxetine (Prozac-) and citalopram (Celexa-) treatment significantly inhibited disease progression of collagen-induced arthritis (CIA) in mice. Research led by Sandra Sacre, Ph.D. from the Brighton and Sussex Medical School (BSMS) in the UK studied the anti-arthritic potential of these drugs, known as selective serotonin reuptake inhibitors (SSRIs), most commonly used to treat depression.

25 Feb 2010

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

Arena Pharmaceuticals, Inc. announced today that its New Drug Application (NDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss, has been accepted for filing by the US Food and Drug Administration (FDA). Arena submitted the lorcaserin NDA on December 22, 2009, and expects to learn the Prescription Drug User Fee Act (PDUFA) date in the next few weeks. The PDUFA date is the target date for the FDA to complete its review of an NDA.

24 Feb 2010

Serotonin News and Research

Latest Serotonin News and Research

Addiction to high calorie fat rich food: likened to cocaine and heroin addiction

USPTO allows Pisgah Labs' patent application regarding imipramine pamoate

Changing drug therapy can help breast cancer patients get full benefit of tamoxifen treatment

Changing drug therapy can help breast cancer patients get full benefit of Tamoxifen

Clinical Data completes NDA submission for vilazodone

IDT: Military application of Transcendental Meditation for preventing war and terrorism

StockPreacher.com: ACAD reports net loss of $8.7M for fourth-quarter of 2009

Antidepressants effective against depression in patients suffering from physical illnesses

Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly

Sleep disorders may increase risk of cardiovascular and metabolic diseases

DSPA's lurasidone NDA accepted for FDA review

AssureRx Health adds CYP1A2 gene to laboratory-developed pharmacogenetic test

Some anti-depressant drugs associated with increased chance of developing cataracts: Study

Moderating treatment response in depression: Role of personality factors

Study indicates GABA neurotransmitters could play a key role in major depressive disorder

Scopolamine drug: A rapid-acting antidepressant for depression symptoms

Arena Pharmaceuticals' lorcaserin NDA: FDA assigns PDUFA date

Fisher Wallace Cranial Stimulator prescribed to patients suffering from depression, anxiety and insomnia

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Serotonin News and Research

Latest Serotonin News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in